Neuronal Control of Bone Remodeling
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Although the brain is well established as a master regulator of homeostasis in peripheral tissues, central regulation of bone mass represents a novel and rapidly expanding field of study. This review examines the current understanding of central regulation of the skeleton, exploring several of the key pathways connecting brain to bone and their implications both in mice and the clinical setting. Our understanding of central bone regulation has largely progressed through examination of skeletal responses downstream of nutrient regulatory pathways in the hypothalamus. Mutations and modulation of these pathways, in cases such as leptin deficiency, induce marked bone phenotypes, which have provided vital insights into central bone regulation. These studies have identified several central neuropeptide pathways that stimulate well-defined changes in bone cell activity in response to changes in energy homeostasis. In addition, this work has highlighted the endocrine nature of the skeleton, revealing a complex cross talk that directly regulates other organ systems. Our laboratory has studied bone-active neuropeptide pathways and defined osteoblast-based actions that recapitulate central pathways linking bone, fat, and glucose homeostasis. Studies of neural control of bone have produced paradigm-shifting changes in our understanding of the skeleton and its relationship with the wider array of organ systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leptin Inhibits Bone Formation through a Hypothalamic Relay
Ducy, P., Amling, M., Takeda, S., Priemel, M., Schilling, A. F., Beil, F. T., Shen, J., Vinson, C., Rueger, J. M., & Karsenty, G. (2000) · Cell · doi:10.1016/s0092-8674(00)81558-5 · Cited by 2,077
Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998 · cited 1×
“Researchers reported a loss in the markedly increased body fat and an increase in whole body BMD in a young girl in response to administration of leptin for 1 year (Farooqi et al. 1999).”
BackgroundLeptin Regulates Bone Formation via the Sympathetic Nervous System
Takeda, S., Elefteriou, F., Levasseur, R., Liu, X., Zhao, L., Parker, K. L., Armstrong, D., Ducy, P., & Karsenty, G. (2002) · Cell · doi:10.1016/s0092-8674(02)01049-8 · Cited by 1,735 · cited 10×
“Thus, changes in SNS activity were implicated in the modulation of bone remodeling and consequently the ob/ob phenotype (Takeda et al. 2002).”
BackgroundMethodInfluentialLeptin regulation of bone resorption by the sympathetic nervous system and CART
Elefteriou, F., Ahn, J. D., Takeda, S., Starbuck, M., Yang, X., Liu, X., Kondo, H., Richards, W. G., Bannon, T. W., Noda, M., et al. (2005) · Nature · doi:10.1038/nature03398 · Cited by 1,311 · cited 4×
“In addition, deficiencies in b2-AR resulted in an increase in cancellous bone volume (Elefteriou et al. 2005), while investigators were able to limit age-related bone loss through the disruption of b2-AR signaling by deletion of adenylyl cyclase-5 (Yan et al.”
BackgroundInfluentialRecombinant human leptin in women with hypothalamic amenorrhea
Welt, C. K., Chan, J. L., Bullen, J., Murphy, R., Smith, P., DePaoli, A. M., Karalis, A., & Mantzoros, C. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040388 · Cited by 908
Ozata, M., Ozdemir, I. C., & Licinio, J. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.5999 · Cited by 739
FSH Directly Regulates Bone Mass
Sun, L., Peng, Y., Sharrow, A. C., Iqbal, J., Zhang, Z., Papachristou, D. J., Zaidi, S., Zhu, L.-L., Yaroslavskiy, B. B., Zhou, H., et al. (2006) · Cell · doi:10.1016/j.cell.2006.01.051 · Cited by 723
Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels
Spanswick, D., Smith, M. A., Groppi, V. E., Logan, S. D., & Ashford, M. L. J. (1997) · Nature · doi:10.1038/37379 · Cited by 628
Osteoprotection by semaphorin 3A
Hayashi, M., Nakashima, T., Taniguchi, M., Kodama, T., Kumanogoh, A., & Takayanagi, H. (2012) · Nature · doi:10.1038/nature11000 · Cited by 606 · cited 2×
“Unsurprisingly, therefore, a decrease in bone density is observed in mice lacking SEMA3A, while systemic administration of SEMA3A into a mouse model of menopause prevents bone loss, suggesting a potential for use as a treatment for diseases related to bone loss (Hayashi et al. 2012).”
BackgroundLeptin is a potent stimulator of bone growth in ob/ob mice
Steppan, C. M., Crawford, D. T., Chidsey-Frink, K. L., Ke, H., & Swick, A. G. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00152-x · Cited by 512
Cited by
Biology of Bone Sarcomas and New Therapeutic Developments
Brown, H. K., Schiavone, K., Gouin, F., Heymann, M.-F., & Heymann, D. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0372-2 · Cited by 163
Decker, A., Askar, H., Tattan, M., Taichman, R., & Wang, H.-L. (2020) · Clinical Oral Investigations · doi:10.1007/s00784-019-03089-3 · Cited by 98
Shi, H., & Chen, M. (2024) · European journal of medical research · doi:10.1186/s40001-024-01918-0 · Cited by 87
Metadata
- Authors
- Corr, A., Smith, J., & Baldock, P.
- Venue
- Toxicologic Pathology
- Publisher
- SAGE Publications
- Published
- 2017-10
- Volume
- 45
- Issue
- 7
- Pages
- 894-903
- ISSN
- 0192-6233 (ISSN-L)
- 1533-1601
- OpenAlex
- W2767834969
- Cited by
- 35
- References
- 17
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuronal Control of Bone Remodeling. https://app.cochat.ai/papers/10.1177/0192623317738708
- The paper
- Corr, A., Smith, J., & Baldock, P. (2017). Neuronal Control of Bone Remodeling. Toxicologic Pathology. https://doi.org/10.1177/0192623317738708
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.